Please login to the form below

Not currently logged in
Email:
Password:

FDA warns Pfizer over adverse reporting

The US FDA has issued Pfizer with a warning letter relating to failures to report adverse events correctly

The US Food and Drug Administration (FDA) has issued Pfizer with a warning letter relating to failures to report adverse events correctly.

The letter, sent to Pfizer on May 26, follows an inspection of the company's New York premises by the US agency, which took place over a period of several weeks almost a year ago.

The inspection was to check Pfizer's procedures for conforming to the FDA's rules that adverse events must be reported to the authority within 15 days.

The letter contained reference to several instances where the pharma giant did not report adverse events relating to Lipitor (atorvastatin calcium) and Lyrica (pregabalin) at all. Further issues included the failure to report issues of visual disturbances as a result of a patient taking Viagra (sildenafil citrate) within the specified 15 day time period.

The US regulator also accused Pfizer of downgrading the classification of some reported events without justification.

In April 2010, the FDA warned Pfizer over its Geodon trials.

10th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics